Evommune Announces Expanded Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Greater China and key Asian countries
PALO ALTO, Calif., March 20, 2024 /PRNewswire/ -- Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into an expanded strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Greater China and additional key Asian countries. The two companies previously entered into a similar agreement for Japan in September, 2023. Under the terms of the new agreement, Evommune is eligible to receive up to $62 million, including a significant upfront and customary milestone payments.
- PALO ALTO, Calif., March 20, 2024 /PRNewswire/ -- Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into an expanded strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Greater China and additional key Asian countries.
- The two companies previously entered into a similar agreement for Japan in September, 2023.
- Under the terms of the new agreement, Evommune is eligible to receive up to $62 million, including a significant upfront and customary milestone payments.
- Evommune has initiated its Phase 1 first-in-human trial, evaluating EVO756 in heathy adults and adults with chronic spontaneous urticaria (CSU).